• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immunotherapy boosts responses in hormone receptor-positive breast cancers.

作者信息

Mitri Zahi, Gelmon Karen A

机构信息

Division of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada.

Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

出版信息

Nat Med. 2025 Feb;31(2):382-383. doi: 10.1038/s41591-024-03441-5.

DOI:10.1038/s41591-024-03441-5
PMID:39901048
Abstract
摘要

相似文献

1
Immunotherapy boosts responses in hormone receptor-positive breast cancers.免疫疗法可增强激素受体阳性乳腺癌的反应。
Nat Med. 2025 Feb;31(2):382-383. doi: 10.1038/s41591-024-03441-5.
2
Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2- negative breast cancer.临床试验数据与新兴免疫治疗策略：激素受体阳性、人表皮生长因子受体2阴性乳腺癌
Breast Cancer Res Treat. 2021 Aug;189(1):1-13. doi: 10.1007/s10549-021-06291-8. Epub 2021 Jul 2.
3
Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.卡培他滨用于激素受体阳性与激素受体阴性乳腺癌。
Cochrane Database Syst Rev. 2021 May 26;5(5):CD011220. doi: 10.1002/14651858.CD011220.pub2.
4
Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.乳腺癌治疗的免疫疗法：检查点阻断、癌症疫苗及联合免疫疗法的未来方向
Clin Adv Hematol Oncol. 2016 Nov;14(11):922-933.
5
Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers.多种癌症/睾丸抗原优先表达于激素受体阴性和高级别乳腺癌中。
PLoS One. 2011 Mar 18;6(3):e17876. doi: 10.1371/journal.pone.0017876.
6
Iron Boosts Antitumor Type 1 T-cell Responses and Anti-PD1 Immunotherapy.铁剂增强抗肿瘤 1 型 T 细胞应答和抗 PD-1 免疫治疗。
Cancer Immunol Res. 2024 Sep 3;12(9):1252-1267. doi: 10.1158/2326-6066.CIR-23-0739.
7
Immunotherapy in Breast Cancer.乳腺癌的免疫治疗。
Int J Mol Sci. 2024 Jul 9;25(14):7517. doi: 10.3390/ijms25147517.
8
A new immunotherapy schedule in addition to first-line hormone therapy for metastatic breast cancer patients in a state of clinical benefit during hormone therapy.对于正在接受激素治疗且临床获益的转移性乳腺癌患者，在一线激素治疗的基础上增加一种新的免疫治疗方案。
J Mol Med (Berl). 2020 Mar;98(3):375-382. doi: 10.1007/s00109-020-01881-3. Epub 2020 Jan 29.
9
Immunotherapy for HER-2 positive breast cancer.HER-2阳性乳腺癌的免疫治疗
Front Oncol. 2023 Mar 16;13:1097983. doi: 10.3389/fonc.2023.1097983. eCollection 2023.
10
Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.三阴性乳腺癌免疫治疗的进展与展望
Front Oncol. 2022 Jun 20;12:919072. doi: 10.3389/fonc.2022.919072. eCollection 2022.

本文引用的文献

1
Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.新辅助纳武单抗与化疗用于早期雌激素受体阳性乳腺癌：一项随机3期试验
Nat Med. 2025 Feb;31(2):433-441. doi: 10.1038/s41591-024-03414-8. Epub 2025 Jan 21.
2
Pembrolizumab and chemotherapy in high-risk, early-stage, ER/HER2 breast cancer: a randomized phase 3 trial.帕博利珠单抗与化疗用于高危早期雌激素受体/人表皮生长因子受体2乳腺癌：一项随机3期试验
Nat Med. 2025 Feb;31(2):442-448. doi: 10.1038/s41591-024-03415-7. Epub 2025 Jan 21.
3
Ribociclib plus Endocrine Therapy in Early Breast Cancer. Reply.
瑞博西尼联合内分泌治疗早期乳腺癌。回复。
N Engl J Med. 2024 Jun 20;390(23):2221-2222. doi: 10.1056/NEJMc2404917.
4
Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer.雌激素受体阳性、人表皮生长因子2阴性乳腺癌的新辅助化疗与免疫治疗
J Clin Oncol. 2024 Aug 1;42(22):2632-2636. doi: 10.1200/JCO.23.02614. Epub 2024 Apr 9.
5
Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer.monarchE研究的长期患者报告结局：阿贝西利联合内分泌治疗作为HR+、HER2-、淋巴结阳性、高危早期乳腺癌的辅助治疗
Eur J Cancer. 2024 Mar;199:113555. doi: 10.1016/j.ejca.2024.113555. Epub 2024 Jan 16.
6
New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer.高危早期激素受体阳性、HER2 阴性乳腺癌的系统性治疗新进展。
Curr Treat Options Oncol. 2023 Jun;24(6):594-610. doi: 10.1007/s11864-023-01082-3. Epub 2023 Apr 15.
7
Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer.低雌激素/孕激素受体状态与阴性雌激素/孕激素受体状态对HER2阴性乳腺癌临床病理特征及生存结果的影响
NPJ Breast Cancer. 2022 Jul 11;8(1):80. doi: 10.1038/s41523-022-00448-4.
8
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.新辅助化疗后残余肿瘤负担与乳腺癌长期生存结局：5161 例患者的多中心汇总分析。
Lancet Oncol. 2022 Jan;23(1):149-160. doi: 10.1016/S1470-2045(21)00589-1. Epub 2021 Dec 11.
9
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.乳腺癌的新辅助化疗、内分泌治疗和靶向治疗：ASCO 指南。
J Clin Oncol. 2021 May 1;39(13):1485-1505. doi: 10.1200/JCO.20.03399. Epub 2021 Jan 28.
10
Pembrolizumab for Early Triple-Negative Breast Cancer. Reply.帕博利珠单抗用于早期三阴性乳腺癌。回复。
N Engl J Med. 2020 Jun 25;382(26):e108. doi: 10.1056/NEJMc2006684.